DOCSLIB.ORG

Bioavailability File : Ornidazole

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioavailability File : Ornidazole FABAD J. Pharm. Sci., 29, 133-144, 2004 SCIENTIFIC REVIEWS Bioavailability File : Ornidazole Sinem Y. HIZARCIO⁄LU*, Zeynep AY*, Mine ÖZYAZICI*° Bioavailability File : Ornidazole Biyoyararlan›m Dosyas› : Ornidazole Summary Özet Ornidazole is a 5-nitroimidazole derivative drug which has anti- Ornidazol, antimikrobiyal etkisi olan 5-nitroimidazol türevi bir microbial action. It is used in the treatment of protozoal infecti- ilaçt›r. Protozoal enfeksiyonlar›n tedavisinde, ayr›ca anaerobik ons, and also in the treatment and prophylaxis of anaerobic bac- bakteriyel enfeksiyonlar›n tedavisi ve profilaksisinde kullan›l›r. terial infections. The mean ornidazole elimination half-life is 12 Ornidazolün ortalama eliminasyon yar› ömrü 12 saattir ve bu hours, significantly longer than that of some nitroimidazole deri- de¤er baz› nitroimidazol türevlerinin eliminasyon yar› ömründen vatives. This is a particular advantage for reducing the dosage frequency and duration of therapy in many of the relevant clini- daha uzundur. Bu özellik, dozaj s›kl›¤›n›n azalt›lmas› ve birçok cal infections. Ornidazole acts by damage of DNA strands or in- klinik enfeksiyonun tedavisinin süreklili¤i aç›s›ndan önemli bir hibition of their synthesis. It is widely distributed in body tissues avantajd›r. Ornidazol, DNA zincirinde hasar oluflturarak veya and fluids, including the cerebrospinal fluid. Ornidazole is meta- DNA sentezini inhibe ederek etki gösterir. Vücutta, serebrospinal bolized in the liver. It is excreted in the urine, mainly as conjuga- s›v› da dahil olmak üzere tüm s›v› ve dokularda genifl olarak da- tes and metabolites, and to a lesser extent in the feces and bile. ¤›l›r. Ornidazol karaci¤erde metabolize olur. At›l›m›, ço¤unlukla Ornidazole is administered orally, vaginally, or intravenously. In konjugatlar› ve metabolitleri halinde idrarla, daha az olarak ise this review, physicochemical, pharmacological and pharmacoki- feçes ve safrayla olur. Ornidazol oral, vajinal ve intravenöz yol- netic properties in addition to bioavailability of ornidazole are la verilebilir. Bu derlemede, ornidazolün fizikokimyasal, farma- discussed. kolojik ve farmakokinetik özellikleri ile birlikte biyoyararlan›m› Key Words : Ornidazole, bioavailability, pharmacokinetics, tart›fl›lm›flt›r. stability, physicochemical properties. Anahtar Kelimeler : Ornidazol, biyoyararlan›m, farmakoki- Received : 17.3.2005 netik, stabilite, fizikokimyasal özellikler. Revised : 3.6.2005 Accepted : 10.6.2005 INTRODUCTION Ornidazole is a 5-nitroimidazole derivative and is used in the treatment of susceptible protozoal infec- Nitroimidazole drugs have been used for over 20 ye- tions and also in anaerobic bacterial infections. It has ars, not only as major antimicrobial drugs but also as been used for amebic liver abscesses, duodenal ul- sensitizers of hypoxic tumors in conjunction with ra- cers, giardiasis, intestinal lambliasis and vaginitis3-5. diotherapy, thus possessing a wider spectrum of Ornidazole has recently been used with success in useful clinical activity than any other antibiotics1,2. patients with active Crohn’s disease6. It is more ef- * Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 35100 Bornova, Izmir-TURKEY ° Corresponding author e-mail: [email protected] 133 H›zarc›o¤lu, Ay, Özyaz›c› fective against amebiasis than metronidazole, which Its pKa was detected as 2.4±0.14,5,11,16,17. is the most commonly used nitroimidazole derivati- ve in therapy7,8. Ornidazole has also been preferred The effect of gamma rays on ornidazole was investi- for surgical prophylaxis because of its longer elimi- gated and it was found that gamma irradiation of nation half-life and excellent penetration into lipidic ornidazole produces free radicals which are detec- tissues versus other nitroimidazole derivatives9,10. table by electron spin resonance (ESR) and appear relatively stable18. The plasma elimination half-life of ornidazole is 11 to 14 hours. Oral absorption of the drug is almost When the literature about stability of ornidazole is complete, with bioavailability of 90% and tmax ran- examined, it can be seen that ornidazole neither yields ging between 2 and 4 hours. Plasma protein binding the nucleus nor undergoes complete decomposition. is approximately 11 to 13%. It is metabolized to five It yields ornidazole diol and intermediate ornidazole metabolites. Two of the major active metabolites are epoxide in alkaline medium. The degradation kinetics M1 and M4, with M1 stemming from an oxidative of ornidazole have been found to be of the first order pathway and M4 via hydrolysis. Ornidazole and its both in solution and solid state (Fig. 2)19,20,21. metabolites are primarily excreted in the urine. Bet- ween 43 and 63% of the dose was recovered from urine, with <4% of the dose recovered as unchanged drug3,11-13. 19 Ornidazole is well tolerated, with the most common Figure 2. Reported degradation products of ornidazole. side effects being nausea, abdominal pain, vertigo, headache, diarrhea, flatulence, and skin rash14,15. The stability studies of ornidazole in alkaline condi- tions were done at a drug concentration of 1 mg/mL Physicochemical Properties in 0.1 M NaOH and the solution was heated at 80°C for 8 hours. The reaction in these conditions was so Ornidazole has a heterocyclic structure consisting of fast that the drug was degraded in a short time. For a nitroimidazole-based nucleus with a 2-hydroxy-3- oxidative conditions, initial studies were done at chloro-propyl group in position 1 and a methyl gro- drug strength of 1 mg/mL in 3% H2O2 and 30% up in position 2. It is synthesized from 5-nitroimida- H2O2. The drug was kept under the conditions of ro- zole derivatives. Ornidazole is known chemically as om temperature for a period of 24 hours. The drug 1-(2-hydroxy-3-chloropropyl)-2-methyl-5-nitroimida- was found to degrade in hydrogen peroxide. It was zole (C H ClN O). Its molecular weight is 219.63 (C 7 10 3 decomposed to an extent of 8% in 3% H2O2, and the 38.28%, H 4.59%, Cl 16.14%, N 19.13%, O 21.85%) and degradation increased to 53% in 30% H2O2. Reports the chemical formula can be seen in Figure 17,12,16. Or- also exist on the stability of the drug in 0.9% sodium nidazole is a white to yellowish microcrystalline chloride and PVC bags under different storage con- powder, with a melting point between 358-360 K. Its ditions22,23. 1% aqueous solution has a pH of approximately 6.6. Ornidazole is soluble in water, ether, ethanol and Identification and Quantification Methods chloroform (2.6, 2.4, over 50, over 50%, respectively). Polarographic, spectrophotometric, colorimetric, potentiometric, microbiologic, thin layer chroma- tographic, high-pressure liquid chromatographic (HPLC) and electrochemical methods have been described for determination of ornidazole in the do- 10,22,24-28 Figure 1. Structural formula of ornidazole. sage forms . Pulse polarography, gas chro- 134 FABAD J. Pharm. Sci., 29, 133-144, 2004 matography (GC) and HPLC procedures are repor- Bactericidal activity appears to be dependent on the ted for its analysis in biological fluids10,27,29. The me- formation of a redox intermediate metabolite in the asurement of ornidazole in biological fluids allows bacterium. This toxic metabolite may interact prima- the dosage to be adjusted in patients suffering from rily with DNA, RNA or intracellular proteins; howe- malabsorption or pathological conditions which ver, its main effects are DNA strand breakage, inhi- modify excretion of the drug. bited repair and ultimately disrupted transcription and cell death3,31-35. Spectrophotometric determination of ornidazole is a simple method and is based on the reduction of a Owing to its similar chemical properties, ornidazole nitro group to a primary amino group which is then shares the same mechanism of action and spectrum reacted with p-dimethylaminobenzaldehyde (p-DA- of microbiological activity as other nitroimidazole BA) to give a red-colored product. During spectrop- agents against anaerobes and protozoa3,31,36-38. The- hotometric studies, a linear correlation was obtained refore, it is a drug of choice for treatment of a large between absorbance and ornidazole concentrations variety of diseases, including intra-abdominal, pul- over the range of 0.75-5 µg/mL24. The GC method monary and brain abscesses, chronic sinusitis and for blood involves a derivatization step, and the me- otitis, and genital tract infections10,32,39. tabolites are not determined30. HPLC method is ra- pid, selective and reproducible, by using an internal Uses and Administrations standard. Furthermore, the method allows metabo- lites to be separated and measured. In HPLC studi- Ornidazole is given by mouth in tablets after food, es, the limits of quantifications were: 0.5µg/mL or intravenously. When given intravenously, soluti- (plasma, cerebrospinal fluid) and 0.6µg/mL (urine) ons of ornidazole should be diluted to 5 mg or less for ornidazole; and 0.05µg/mL (plasma, cerebrospi- per mL and 100 or 200 mL infused over 15 to 30 mi- 12 nal fluid) and 0.3µg/mL (urine) for both M4 and nutes. It has also been given by vaginal pessary . M110,26. Electrochemical method for the determinati- on of ornidazole has the advantage of being rapid, In amebiasis, 500 mg of ornidazole is given twice da- simple and inexpensive28. ily by mouth for 5 to 10 days. Patients with amebic dysentery may be given 1.5 g as a single daily dose Pharmacology for 3 days. In severe amebic dysentery and amebic liver abscess, ornidazole may be given by intraveno- Mechanism of action us infusion in a dose of 0.5 to 1 g initially, followed by 500 mg every 12 hours for 3 to 6 days12,40,41. 5-Nitroimidazoles belong to the nitroheterocyclic fa- mily of compounds widely used for the treatment or In giardiasis, 1 or 1.5 g of drug is given by mouth as 12,42-44 prophylaxis of infections due to anaerobic bacteria a single daily dose for 1 or 2 days .
Load more

Recommended publications
  • Antibiotic Dispensation Without a Prescription Worldwide: a Systematic Review
    antibiotics Review Antibiotic Dispensation without a Prescription Worldwide: A Systematic Review Ana Daniela Batista 1, Daniela A. Rodrigues 2 , Adolfo Figueiras 3,4,5 , Maruxa Zapata-Cachafeiro 3,4 ,Fátima Roque 2,6 and Maria Teresa Herdeiro 7,* 1 Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 2 Research Unit for Inland Development, Polytechnic Institute of Guarda (UDI/IPG), 6300-559 Guarda, Portugal; [email protected] (D.A.R.); [email protected] (F.R.) 3 Department of Preventive Medicine and Public Health, University of Santiago de Compostela, 15702 Santiago de Compostela, Spain; adolfo.fi[email protected] (A.F.); [email protected] (M.Z.-C.) 4 Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiology and Public Health-CIBERESP), 28001 Madrid, Spain 5 Health Research Institute of Santiago de Compostela (IDIS), 15702 Santiago de Compostela, Spain 6 Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal 7 Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal * Correspondence: [email protected] Received: 7 October 2020; Accepted: 6 November 2020; Published: 7 November 2020 Abstract: Antibiotic resistance still remains a major global public health problem and the dispensing of antibiotics without a prescription at community pharmacies is an important driver of this. MEDLINE, Pubmed and EMBASE databases were used to search and identify studies reporting the dispensing of non-prescribed antibiotics in community pharmacies or drugstores that sell drugs for human use, by applying pharmacy interviews/questionnaires methods and/or simulated patient methods.
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]
  • New Approaches to the Development of Anti-Protozoan Drug Candidates: a Review of Patents
    J. Braz. Chem. Soc., Vol. 21, No. 10, 1787-1806, 2010. Printed in Brazil - ©2010 Sociedade Brasileira de Química 0103 - 5053 $6.00+0.00 Review New Approaches to the Development of Anti-Protozoan Drug Candidates: a Review of Patents Elaine F. F. da Cunha,* Teodorico C. Ramalho,* Daiana T. Mancini, Emanuella M. B. Fonseca and Aline A. Oliveira Departamento de Química, Universidade Federal de Lavras, 37200-000 Lavras-MG, Brazil As doenças causadas por protozoários afetam hoje em dia uma grande parcela da população mundial, provocando muitas mortes e exercendo grande influência na qualidade de vida e no desenvolvimento de muitos países. Essas doenças afetam principalmente países pobres e por isso, a pesquisa e o desenvolvimento de novos fármacos são negligenciados. De fato, a maioria das drogas usadas no tratamento dessas doenças data de décadas passadas e apresentam muitas limitações, incluindo o aparecimento da resistência às drogas. Este artigo tem como foco os mais recentes desenvolvimentos publicados no campo de patentes, entre 2001-2008, com especial atenção a promissores compostos atuando contra tripanossomíase, leishmaniose, malária, toxoplasmose, amebíase, giardíase, balantidíase e pneumocistose. Protozoan infections are parasitic diseases that affect hundreds of millions of people worldwide, but have been largely neglected for drug development because they affect poor people in poor regions of the world. Most of the current drugs used to treat these diseases are decades old and have many limitations, including the emergence of drug resistance. This review will focus on the most recent developments, from 2001 to 2008, published in the field of patents and publications, paying particular attention to promising compounds acting against trypanosomiasis, leishmaniasis, malaria, toxoplasmosis, amebiasis, giardiasis, balantidiasis and pneumocystosis, their chemistry and biological evaluation, and to new chemical and pharmaceutical processes.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • Antiparasitic Treatments in Pregnant Women: Update and Recommendations E Boitel, Guillaume Desoubeaux
    Antiparasitic treatments in pregnant women: Update and recommendations E Boitel, Guillaume Desoubeaux To cite this version: E Boitel, Guillaume Desoubeaux. Antiparasitic treatments in pregnant women: Up- date and recommendations. Médecine et Maladies Infectieuses, Elsevier Masson, In press, 10.1016/j.medmal.2018.09.008. hal-02439523 HAL Id: hal-02439523 https://hal.archives-ouvertes.fr/hal-02439523 Submitted on 17 Jan 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Médicaments antiparasitaires chez la femme enceinte : actualités et recommandations Antiparasitic treatments in pregnant women: update and recommendations E Boitel1, G Desoubeaux1,* 1CHU de Tours, Parasitologie – Mycologie – Médecine tropicale, 37044 Tours - France *Corresponding author: [email protected] Service de Parasitologie – Mycologie –Médecine tropicale Hôpital Bretonneau, Bâtiment B2A 1er étage 2 boulevard Tonnellé 37044 CHU de Tours Cedex 9 - FRANCE Téléphone : +33(0)2 47 47 39 27 Fax : +33(0)2 47 47 80 82 Mots clés : hypotrophie ; morts fœtales in utero ; mutagénicité ; tératogénicité ; paludisme Keywords: fetal death; low birth weight; mutagenicity; teratogenicity; malaria RESUME Les parasitoses constituent une importante cause de morbi-mortalité dans le monde, et plus particulièrement dans les pays à faibles ressources où la prévalence de telles infections est très élevée.
    [Show full text]
  • Design, Preparation, and Evaluation of a Novel 99Mtcn Complex of Ciprofloxacin Xanthate As a Potential Bacterial Infection Imaging Agent
    molecules Article Design, Preparation, and Evaluation of a Novel 99mTcN Complex of Ciprofloxacin Xanthate as a Potential Bacterial Infection Imaging Agent Si’an Fang, Yuhao Jiang, Qianqian Gan, Qing Ruan, Di Xiao and Junbo Zhang * Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China; [email protected] (S.F.); [email protected] (Y.J.); [email protected] (Q.G.); [email protected] (Q.R.); [email protected] (D.X.) * Correspondence: [email protected]; Tel.: +86-10-6220-8126 Academic Editor: Rodica Olar Received: 31 October 2020; Accepted: 7 December 2020; Published: 10 December 2020 Abstract: In order to seek novel technetium-99m bacterial infection imaging agents, a ciprofloxacin xanthate (CPF2XT) was synthesized and radiolabeled with [99mTcN]2+ core to obtain the 99mTcN-CPF2XT complex, which exhibited high radiochemical purity, hydrophilicity, and good stability in vitro. The bacteria binding assay indicated that 99mTcN-CPF2XT had specificity to bacteria. A study of biodistribution in mice showed that 99mTcN-CPF2XT had a higher uptake in bacterial infection tissues than in turpentine-induced abscesses, indicating that it could distinguish bacterial infection from sterile inflammation. Compared to 99mTcN-CPFXDTC, the abscess/blood and abscess/muscle ratios of 99mTcN-CPF2XT were higher and the uptakes of 99mTcN-CPF2XT in the liver and lung were obviously decreased. The results suggested that 99mTcN-CPF2XT would be a potential bacterial infection imaging agent. Keywords: ciprofloxacin xanthate; quinolones; infection imaging; 99mTc-radiolabeling 1. Introduction Public health advanced during the eighteenth and nineteenth centuries and with antibiotics discovered in the twentieth century, treatment of infection has been highly improved.
    [Show full text]
  • Parasitic Infections (1 of 14)
    Parasitic Infections (1 of 14) 1 Patient presents w/ signs & symptoms suggestive of GI parasitic infection 2 DIAGNOSIS No ALTERNATIVE Is a GI parasitic infection DIAGNOSIS confi rmed? Yes Protozoal or helminthic infection? Protozoal Infection Helminthic Infection A Rehydration & nutrition B Prevention PHARMACOLOGICAL PHARMACOLOGICAL THERAPY FOR THERAPY FOR PROTOZOAL HELMINTHIC INFECTIONS INFECTIONS ©See page 3 MIMSSee page 3 B1 © MIMS 2019 Parasitic Infections (2 of 14) 1 SIGNS & SYMPTOMS OF GI PARASITIC INFECTIONS GI Symptoms • Abdominal pain, diarrhea, dysentery, fl atulence, malabsorption, symptoms of biliary obstruction Nonspecifi c Symptoms • Fever, malaise, fatigue, anorexia, sweating, wt loss, edema & pruritus • Some patients may be asymptomatic PARASITIC INFECTIONS PARASITIC 2 DIAGNOSIS Clinical History • Attempt to elicit a history of possible exposure, especially for helminthic infections, eg eating undercooked meat, source of drinking water, swimming in fresh water where certain parasites may be endemic • Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients Host Susceptibility Factors in GI Parasitic Infections • Nutritional status • Intercurrent disease • Pregnancy • Immunosuppressive drugs • Presence of a malignancy Physical Exam Findings • Pallor • Hepatomegaly • Ascites • Ileus • Rectal prolapse Lab Tests Microscopic Exam of Stools • Fundamental to the diagnosis of all GI infections - A minimum of 3 stool specimens, examined by trained personnel using a concentration & a permanent stain
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Compounds Dimetridazole, Metronidazole, Secnidazole
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1985, p. 561-564 Vol. 28, No. 4 0066-4804/85/100561-04$02.00/0 Copyright © 1985, American Society for Microbiology Comparative Evaluation of the 2-Methyl-5-Nitroimidazole Compounds Dimetridazole, Metronidazole, Secnidazole, Ornidazole, Tinidazole, Carnidazole, and Panidazole against Bacteroides fragilis and Other Bacteria of the Bacteroides fragilis Group LIISA JOKIPII1* AND ANSSI M. M. JOKIPII2 Department of Serology and Bacteriology, University of Helsinki, 00290 Helsinki,1 and Department of Medical Microbiology, University of Turku, Turku,2 Finland Received 13 May 1985/Accepted 30 July 1985 Tube-dilution MICs of seven 2-methyl-5-nitroimidazole compounds varying at the 1-substitution were determined against Bacteroides fragilis. Activities on a molar basis were ranked: tinidazole > panidazole > ornidazole > metronidazole 2 secnidazole > carnidazole > dimetridazole. Geometric mean MICs varied from 0.5 to 6.6 ,uM, and MICs against individual strains varied up to 50-fold between compounds. In general, the MIC of each drug correlated with that of each of the other drugs, but with tinidazole the correlation coefficients tended to be small and were not significant versus metronidazole and secnidazole. MICs against 14 other bacteria of the B. fragilis group, including B. distasonis, B. ovatus, B. thetaiotaomicron, B. uniformis, and B. vulgatus, were within the range determined for B. fragilis. Increased awareness of anaerobic infections and the dem- N.Y.; carnidazole (R 25831; batch A 8301) was from Janssen onstration of the excellent activity of metronidazole against Pharmaceutica N.V., Beerse, Belgium; and panidazole a wide range of obligately anaerobic bacteria (4-6, 18) have (batch 4 RI/A) was from Ward Blenkinsop & Co.
    [Show full text]
  • Manuscript Type: Review DOI: 10.5152/Eurjther.2019.18075 Title: Drug
    Manuscript type: Review DOI: 10.5152/EurJTher.2019.18075 Title: Drug Resistance in Parasitic Diseases Running head: Drug resistance Hatice Ertabaklar, Erdoğan Malatyalı, Sema Ertuğ, Aydın Adnan Menderes University, Faculty of Medicine Department of Parasitology, Aydın, Turkey Corresponding author: Hatice Ertabaklar E-mail: [email protected] Acknowledgement: This manuscript is an activity of Society for Clinical Microbiologists of Turkey (KLİMUD), Medical Parasitology Study Group. Abstract The current strategy in the prevention of parasitic diseases is mostly chemotherapy, because of the lacking or ineffectiveness of vaccines for life threating parasitic diseases. The chemotherapeutic options are being disrupted by drug resistance and that increase the need for novel drugs in parasitological treatments. The most common resistance mechanisms are decreased drug uptake, export of drugs from parasites, genetic modifications, loss of drug activity, and alteration of the drug target. In order to develop new strategies to control parasitic diseases, drug resistance mechanisms should be well defined. Moreover, it will lead to giving new effective treatment options for clinicians. In recent years, isolation and characterisation of resistance-related genes and proteins greatly increased our knowledge. In this review, we have mostly focused on new studies and common parasitic diseases. Keywords: Drug resistance, parasitic diseases, chemotherapy Introduction Parasitic diseases have significant health, social and economic impacts globally, especially in tropical countries. Protozoan and helminthic diseases (mostly malaria and schistosomiasis) are responsible for almost 1.1 million deaths. Moreover, globally distributed protozoan parasites cause a high rate of disability-adjusted life years (1). The burden of parasitic diseases rises regularly due to the lack of licensed vaccines and effective drugs.
    [Show full text]
  • Development and Validation of Stability Indicating RP-HPLC (PDA) Method for Estimation of Rifaximin and Ornidazole in Bulk and Combined Tablet Dosage Formulation
    International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.05, pp 85-95, 2018 Development and Validation of Stability Indicating RP-HPLC (PDA) Method for Estimation of Rifaximin and Ornidazole in Bulk and Combined Tablet Dosage Formulation P.G.Sunitha1*, S.Hemalatha2, K.Rama3 1,2Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Affiliated to The Dr. MGR Medical University, Chennai-03, India 3Analytical Research and Development, DGM, SaimirraInnopharm Pvt Ltd, Chennai-98, India Abstract : An isocratic stability indicating RP-HPLC(PDA) method was developed and validated for the determination of Rifaximin and Ornidazole in pharmaceutical dosage form. Isocratic elution was performed using the mobile phase Ammoniumformate buffer(pH 7.2) and Acetonitirile (55:45 v/v).Linearity was observed in the concentration range of 50-150µg ml-1 (0.999) for Rifaximin and 62.5 -875.5µg ml-1(0.999) for Ornidazole. Rifaximin and Ornidazole were subjected to stress conditions of degradation such as acidic, alkaline, oxidation, photolytic and thermal degradation. The drug combination was found to be more sensitive towards acidic degradation. The method was validated as per ICH Guidelines. The recovery was in good agreement with the labeled amount in the pharmaceutical formulation. The proposed method is simple, precise, specific, accurate and robust for the determination of Rifaximin and Ornidazolein pharmaceutical dosage form. Key words : RP-HPLC, Rifaximin, Ornidazole, Stability indicating, Validation, Quantification. Introduction Ornidazole(ONZ) is a 5-nitroimidazole derivative1.Chemically ONZ is 1-(3-chloro-2-hydroxypropyl)-2- methyl-5 nitroimidazole(Fig.1).It is used in the treatment of amoebic dysentery, bacterial vaginosis, amoebiasis, giardiasis and trichomoniasis2.
    [Show full text]
  • Method Development and Validation of Ciprofloxacin Hcl and Ornidazole by UFLC in Combined Dosage Form
    Original Article Method Development and Validation of Ciprofloxacin HCl and Ornidazole by UFLC in Combined Dosage Form Palled Mahesh Shivabasappa1,*, Hadaki Diksha1, Mahendra Kumar Chouhan2, Sunil Satyappa Jalalpure2, Shailendra Suryawanshi Sanjay1 1Department of Pharmaceutical Chemistry, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, Karnataka, INDIA. 2Dr. Prabhakar Kore Basic Science Research Center, Belagavi, Karnataka, INDIA. ABSTRACT Background: The combination of Ciprofloxacin and Ornidazole is used for the effective treatment of intra-abdominal infections. Many branded and generic combined dosage formulations of Ciprofloxacin and Ornidazole are available in market. Objective: To develop and validate rapid, sensitive, simple and accurate reverse phase ultra-fast liquid chromatographic method for the determination of Ciprofloxacin and Ornidazole in combined dosage forms. Methods: The separation was carried out by using Phenomenex Luna C18 (250×4.6 mm, 5 µm) column as stationary phase and acetonitrile: methanol: 0.1% formic acid as a mobile phase in ratio of 35:35:30 % v/v/v. The analysis was performed at flow rate of 0.8 ml/min using PDA detector at 300 nm. The column temperature was maintained at 20°C for better separation and resolution. Results: The retention time for Ciprofloxacin HCl and Ornidazole was found to be 2.1 min and 4.2 min respectively. The developed method was validated with respect to specificity, linearity and range, precision, robustness and accuracy according to ICH guidelines. The method was found to be linear between the concentration ranges of 2-10 µg/ml with correlation coefficient of 0.999. The % relative standard deviation of precision and robustness was found to be less than 2%.
    [Show full text]